Treace Medical (TMCI) Officer Form 4: 373,807 shares reported

Rhea-AI Filing Summary

Sean F. Scanlan, identified as Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a common stock transaction dated 08/09/2025 on a Form 4. The filing records a transaction coded F and shows the reporting line items 9,814 with a marker D and a post-transaction beneficial ownership total of 373,807 shares held directly.

The form includes an explanatory footnote that the beneficial ownership figure includes 284,798 restricted stock units. The filing was executed by an attorney-in-fact on behalf of Mr. Scanlan as indicated on the form.

Positive

• Transparent disclosure: The Form 4 clearly reports the officer's transaction and resulting ownership totals.
• Large equity stake reported: The filing shows 373,807 shares beneficially owned directly, including 284,798 restricted stock units, clarifying the composition of holdings.

Negative

• Disposition indicated: The table includes a line with 9,814 and a D marker, indicating a reported disposal on the face of the table.
• Price field shows $0: The tabular price entry is listed as $0, which lacks explanatory context in the filing text provided.

Insights

Corporate Governance Expert

TL;DR: Routine insider transaction disclosure showing the officer retains substantial direct ownership, including many restricted stock units.

The Form 4 documents a security change for the Chief Innovation Officer with a post-transaction direct holding of 373,807 shares, of which the filing explicitly states 284,798 are restricted stock units. The report uses transaction code F and references 9,814 alongside a D designation. From a governance perspective, this filing provides transparent reporting of officer ownership and the composition of holdings; no governance breach or procedural irregularity is apparent from the text provided.

Securities Analyst

TL;DR: Disclosure shows an insider ownership update with a sizable RSU component; the reported numbers are clearly stated but not materially transformative.

The document discloses a common stock transaction dated 08/09/2025 and a resulting direct beneficial ownership of 373,807 shares. The explicit note that 284,798 of those are restricted stock units clarifies that a large portion of the holding is equity compensation rather than fully liquid shares. The filing lists 9,814 with a D indicator and a price field shown as $0 in the table; the filing does not provide additional context for that line beyond the tabular entries.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scanlan Sean F.

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/09/2025		F		9,814	D	$0	373,807(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 284,798 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did TMCI insider Sean Scanlan report on the Form 4?

The Form 4 reports a common stock transaction dated 08/09/2025 with transaction code F and a table line showing 9,814 with a D designation.

How many Treace Medical Concepts (TMCI) shares does Sean Scanlan beneficially own after the reported transaction?

The filing shows a post-transaction direct beneficial ownership of 373,807 shares.

Does the Form 4 indicate restricted stock units for Sean Scanlan?

Yes. The explanatory footnote states the beneficial ownership total includes 284,798 restricted stock units.

Who filed the Form 4 on behalf of Sean Scanlan?

The form bears a signature block executed by Lisa Taylor as Attorney-in-fact for Sean Scanlan, as shown on the document.

What does the price column show for the reported transaction?

The tabular entry for price is listed as $0 in the provided table; no further explanation is included in the text provided.